
Australian Epilepsy Project featured on ABC's 7:30 program
The Australian Epilepsy Project is competing for Medical Research Future Fund support to improve epilepsy diagnosis throughout Australia.
A public lecture will explore sudden unexplained death in epilepsy – the most common epilepsy-related cause of premature death.
Professor Terry O’Brien will present ‘Sudden unexpected death in epilepsy: How translational research is finding answers’ on Thursday 29 October via Zoom.
Uncontrolled epileptic seizures can cause death by disrupting heart and lung function. Exactly how this happens is the topic of Professor O’Brien’s research. In his lecture, he will describe evidence-based interventions that are being developed to reduce the risk of sudden unexplained death in people with epilepsy.
Sudden unexpected death in epilepsy – known as ‘SUDEP’ – is death that cannot be attributed to another disease, injury or accident (such as drowning). SUDEP is the most common epilepsy-related cause of premature death.
Young people with epilepsy are up to 40 times more likely to die suddenly than people of the same age who don’t have epilepsy. Around 150 000 people in Australia live with active epilepsy. An estimated 50–100 of them die from SUDEP each year.
Professor O’Brien is a specialist in neurology and clinical pharmacology at Monash University and Alfred Health. He is part of the Australian Epilepsy Project, and he has an honorary position at the University of Melbourne.
The lecture is part of a series of public lectures presented each year by Monash University’s Central Clinical School.
The lecture will be at 6–7pm (AEST) on Thursday 29 October. This includes 45 minutes for the lecture, and 15 minutes for questions and answers.
The lecture is free and open to the public. It will be held online using Zoom.
To find out more about Prof. O’Brien’s lecture, visit the 2020 Central Clinical School Public Lecture website or email julia.veitch@monash.edu
The Australian Epilepsy Project is competing for Medical Research Future Fund support to improve epilepsy diagnosis throughout Australia.
A Carbon Cybernetics implant that stimulates and records information from single brain cells is being developed to help manage epilepsy.
Epi-Minder has raised $A10 million to develop a device for seizure detection and prediction, which is now undergoing a Phase I clinical trial.